Cybin Inc.
UK-based COMPASS Pathways has secured $285 million in funding through a private placement to support its research in psychedelic medicines.
Researchers at Lund University have developed a new measuring technique to understand what happens to the neurons in rats’ brains when they are given psychedelics.
The first-ever Professional Practice Guidelines for psychedelic therapy in the US have been published by the American Psychedelic Practitioners Association (APPA) and BrainFutures.
PharmAla Biotech Holdings has announced that it has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia.
Marking a world first, researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin as a treatment for gambling addiction with the support of funding from...
Silo Pharma has announced it has advanced the formulation development for its therapeutic drug, SPC-15, which utilises ketamine.
A new Phase 1 study looking at psilocybin in combination with psychological support as a treatment for females with anorexia nervosa has shown positive results.
The final cohort of patients has been dosed in Cybin’s Dosing Phase 2 Trial investigating CYB003 – an investigational deuterated analogue of psilocybin – as a...
Alcohol use disorders (AUD) are estimated to affect around 237 million people across the globe, with 3 million deaths each year attributed to the harmful use...
